Market Overview:
Cardiology Stem Cells Market Size exceeded USD 2.8 Billion in 2022 and is projected to showcase a CAGR of over 7.1% from 2023 to 2032. By the end of the forecast period, the market is expected to reach a valuation of around USD 5.6 Billion.
To get more info about this report -
Cardiology is a branch of medicine concerned with the study, diagnosis, and treatment of heart-related conditions. The use of stem cells in the treatment of heart disease is one area of cardiology that has gained increasing attention in recent years.
Stem cells are distinct cells that have the ability to differentiate into various cell types such as heart muscle cells, blood vessels, and other types of tissue. Because of this, they are a promising tool for repairing damaged or diseased tissue in the heart.
Stem cells of various types, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells, can be used in cardiology. Adult stem cells can be found in many tissues throughout the body, including bone marrow and adipose tissue.
Growth Factor:
The cardiology stem cells market growth factors are the various factors that are driving the market's growth. The increasing prevalence of cardiovascular diseases around the world is one of the major factors driving the growth of this market. Cardiovascular diseases are the leading cause of death worldwide, accounting for approximately 17.9 million deaths each year, according to the World Health Organization (WHO). As a result, there is an increasing demand for effective treatments for these conditions, with cardiology stem cell therapy emerging as a promising option.
The increasing investment in research and development activities in this field is another key growth factor for the cardiology stem cells industry. Several biotechnology and pharmaceutical companies are heavily investing in research and development.
|
Cardiology Stem Cells Market Value Insights |
|
|
Report Coverage |
Details |
|
Base Year |
2022 |
|
Market Size in 2022 |
USD 2.8 Billion |
|
Forecast Period |
2023 to 2032 |
|
CAGR (2023 to 2032) |
7.1% |
|
Forecast Year Value, 2032 |
USD 5.6 Billion |
|
Historical Data for |
2019 to 2022 |
|
Segment Covered |
Type of Cell, Application, Source, End User, Region |
|
Companies Covered |
|
To get more info about this report -
By Type of Cell: Usage of Adult Stem Cells Reduces the threat of Rejection and Lowers threat of Complications:
Adult stem cells dominated the global cardiology stem cells market in 2022 in terms of cell type. Adult stem cells can be extracted easily from a patient's own body, removing the need for a donor and lowering the risk of rejection. Furthermore, when compared to embryonic stem cells, these have a lower risk of developing tumors. This reduces the possibility of complications with cell-based therapies.
Regional Overview:
North America is currently the largest market for cardiology stem cells, owing to the region's high prevalence of cardiovascular diseases, as well as the presence of a well-established healthcare infrastructure and a supportive regulatory environment. The United States is the largest contributor to the North American market, accounting for the vast majority of the region's revenue.
The Asia Pacific region is expected to see significant growth in the cardiology stem cell market in the coming years, owing to the region's growing awareness and acceptance of stem cell therapy, as well as a large patient pool with cardiovascular diseases. The major contributors to the Asia Pacific market are China and Japan.
Key Development:
- In December 2022, Bio Cardia, Inc. has been granted FDA approval to initiate a first-in-human phase I/II clinical trial of its Neurokinin-1 receptor positive (NK1R+) allogeneic human mesenchymal stem cell (MSC) therapy for the treatment of ischemic heart failure individuals.
- In May 2021, the Sociedad Espanola de Medicina Regenerativa y Terapia Celular and Kalyagen has announced the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction Either Individually or in Combination in Patients with Heart Failure," to assess the use of stem cell therapies in heart failure patients. STEMREGEN is a natural stem cell enhancer that stimulates endogenous stem cell mobilization to increase the number of circulating stem cells.
Top companies includes in the global cardiology stem cells market:
- Astellas Pharma, Inc.
- STEMCELL Technologies
- Cellular Engineering Technologies
- BioTimes, Inc.
- Takara Bio, Inc.
- U.S. Stem Cell, Inc.
- BrainStorm Cell Limited.
- Cytori Therapeutics, Inc.
- Lisata Therapeutics
- Bio Cardia, Inc.
To get more info about this report -
In-depth analysis of cardiology stem cells market along with industry coverage and forecasting for the following segments:
Market Value Insights, By Type of Cell
- Embryonic Stem Cells
- Adult Stem Cells
- Induced Pluripotent Stem Cells
- Cord Blood Stem Cells
- Amniotic Fluid Stem Cells
Market Value Insights, By Application
- Heart Failure
- Myocardial Infarction
- Critical Limb Ischemia
- Others
Market Value Insights, By Source
- Autologous
- Allogenic
Market Value Insights, By End User
- Pharmaceutical & Biotechnology Companies
- Hospitals & Cell Banks
- Academic & Research Institutes
Market Value Insights, By Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America